Study of Efficacy and Safety of CVAA489 in Hypertensive Patients

Inclusion Criteria: * Male or female, above 18 years of age * Diagnosis of essential hypertension * Newly diagnosed, * Previously untreated, or Currently untreated (not on regular antihypertensive treatment during the previous at least 1-month period) * Written informed consent Exclusion Criteria: * Known or suspected secondary hypertension * eGFR lower than 30 mL/min * Use of any other hypertension treatments during the enrollment and need for using the related treatments during the study phase * History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes. (i.e. valsartan, amlodipine, hydrochlorothiazide) * History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases. * Use of other investigational drugs within 5 half-lives of enrollment, or within 30 days until the expected PD effect has returned to baseline, whichever is longer.Pregnant or nursing (lactating) women * Other protocol-defined inclusion/exclusion criteria may apply.